Companies /Healthcare

Tempus AI, Inc. Class A Common Stock

NASDAQ: TEM Health Information Services
$64.04
▼ $6.65 (−9.41%) today
Markets closed · 8:00am ET

Q4 2025 Earnings

Reported Feb 24, 2026, 4:01pm ET · SEC source
$-0.04
Beat +22.03%
EPS · est. $-0.05
$367.2M
Beat +1.05%
Revenue · est. $363.4M
−12.1%
Trailing market
TEM vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−3%0+3%+6%Feb 24Feb 25report 4:01pm ETearnings+0.7%−3.7%
−3%0+3%+6%Feb 24Feb 25earnings+0.7%−3.7%
TEM −3.7%S&P 500 +0.7%
−3%0+3%+6%Feb 24Feb 25report 4:01pm ETearnings+1.2%−3.7%
−3%0+3%+6%Feb 24Feb 25earnings+1.2%−3.7%
TEM −3.7%NASDAQ +1.2%
−10%−5%0+5%Feb 23Mar 4report 4:01pm ETearnings−0.2%−6.3%
−10%−5%0+5%Feb 23Mar 4earnings−0.2%−6.3%
TEM −6.3%S&P 500 −0.2%
−10%−5%0+5%Feb 23Mar 4report 4:01pm ETearnings+0.7%−6.3%
−10%−5%0+5%Feb 23Mar 4earnings+0.7%−6.3%
TEM −6.3%NASDAQ +0.7%
−7.32%
Day of report
+3.17%
Next session
−4.51%
One week
−20.65%
30 days

S&P 500 over the same 30 days: −8.52%.

Did TEM Beat Earnings? Q4 2025 Results

Tempus AI closed out 2025 with a quarter that <a href="https://247wallst.com/investing/2026/02/24/live-earnings-will-tempus-ai-surprise-wall-street-tonight/">Wall Street had been watching closely</a>, reporting Q4 revenue of $367.21 million — an 83% year-over-year surge — while narrowing its adjusted loss to just $0.04 per share, well ahead of the $0.14 analysts had anticipated. The headline driver was a remarkable acceleration in the Diagnostics segment, which posted $266.86 million in Q4 revenue, up 121.6% year-over-year, powered by 29% Oncology volume growth and early momentum in minimal residual disease testing, which hit roughly 4,700 tests in the quarter alone. For the full year, revenue reached $1.27 billion, up 83.4%, while Q4 Adjusted EBITDA turned positive at $12.89 million — a meaningful inflection for a company that has carried substantial losses. Despite a full-year net loss of $245.03 million, management struck a confident tone on the path forward, guiding 2026 revenue to approximately $1.59 billion with Adjusted EBITDA of roughly $65 million, signaling that the company's dual diagnostics and data licensing model is beginning to translate growth into financial discipline.

Key Takeaways
  • Oncology testing volume growth of 29% year-over-year in Q4
  • Hereditary testing volume growth of 23% year-over-year in Q4
  • Insights (data licensing) grew 69.5% in Q4 excluding AstraZeneca warrant impact
  • Ambry Genetics acquisition contributed to inorganic diagnostics growth
  • MRD testing volume up 56% quarter-over-quarter
  • Net Revenue Retention of 126%

“In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space. The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world.”

Tempus AI CEO, on the earnings call

Forward Guidance & Outlook

Tempus provided full year 2026 revenue guidance of approximately $1.59 billion, representing ~25% annual growth. The company expects 2026 Adjusted EBITDA to be approximately $65 million, indicating a clear path toward sustained profitability after turning Adjusted EBITDA positive in Q4 2025.

TEM YoY Financials

Revenue$367.2M
Gross Profit$237.7M
Operating Income$-61,413,000
Net Income$-54,166,000

TEM Revenue by Segment

Diagnostics$266.9M+121.6%
Genomics
Oncology Testing (Tempus genomics)
Oncology Testing (Tempus Genomics)
Oncology Testing
Hereditary Testing (Ambry Genetics)
Data and Applications$100.4M+25.1%
Data and Services

Figures from SEC filings and company reports. Not investment advice.